Lp-PLA₂ Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus

References

• Suman RK, Mohanty IR, Borde MK, Maheshwari U, Deshmukh YA. Development of an experimental model of diabetes co-existing with metabolic syndrome in rats. Adv Pharmacol Sci. 2016;2016:9463476.26880906
   PubMed Web of Science ®Google Scholar
• Zhang X, Lerman LO. The metabolic syndrome and chronic kidney disease. Transl Res Elsevier Inc. 2017;183:14–25. doi:10.1016/j.trsl.2016.12.004
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(SUPPL.1):67–74. doi:10.2337/dc13-S067
   PubMed Web of Science ®Google Scholar
• Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. Curr Vasc Pharmacol. 2012;10(6):684–686. doi:10.2174/15701611280352086423259553
   PubMed Web of Science ®Google Scholar
• Yoon YS, Park HS, Yun KE, Kim SB. Obesity and metabolic syndrome-related chronic kidney disease in nondiabetic, nonhypertensive adults. Metabolism. 2009;58(12):1737–1742. doi:10.1016/j.metabol.2009.05.02919615700
   PubMed Web of Science ®Google Scholar
• Zhang S, Ritter LR, Ibragimov AI. Foam cell formation in atherosclerosis: HDL and macrophage reverse cholesterol transport. Discret Contin Dyn Syst - Ser S. 2013;2013:825–835.
   Google Scholar
• Kuate D, Kengne APN, Biapa CPN, Azantsa BGK, Abdul Manan Bin Wan Muda W. Tetrapleura tetraptera spice attenuates high-carbohydrate, high-fat diet-induced obese and type 2 diabetic rats with metabolic syndrome features. Lipids Health Dis.2015;14:50 BioMed Central. doi:10.1186/s12944-015-0051-026003803
   PubMed Web of Science ®Google Scholar
• Wihastuti TA, Sargowo D, Widodo MA, Heriansyah T, Soeharto S, Ardi AI. Subchronic toxicity of ganoderma lucidum polysaccharide peptide (PsP) to liver physiology and histopathology imaging of liver on rattus norvegicus strain wistar rats. Biomed Pharmacol J. 2014;7(2):417–424. doi:10.13005/bpj/506
   Google Scholar
• Pfeilera S, Winkelsb H, Kelma M, Norbert G. IL-1 family cytokines in cardiovascular disease. Cytokine. 2017;In press:22.
   Google Scholar
• Heriansyah T, Siswanto BB, Santoso A, et al. Ox-LDL, lysophospatidyl choline platelet activating factor, il-6 expression level and foam cell number with darapladib treatment in early development of atherosclerosis: in vivo study for type 2 diabetes mellitus model. J Hong Kong Coll Cardiol. 2016;24(2):64–73.
   Google Scholar
• Heriansyah T, Wihastuti TA, Siswanto BB, et al. Lowering inflammation level by Lp-PLA2 inhibitor (Darapladib) in early atherosclerosis development : in vivo rat type 2 diabetes mellitus model. J Cardiovasc Dis Res. 2017;8(2):50–55. doi:10.5530/jcdr.2017.2.12
   Google Scholar
• Feigerlová E, Battaglia-Hsu S-F. IL-6 signaling in diabetic nephropathy: from pathophysiology to therapeutic perspectives. Cytokine Growth Factor Rev. 2017;37:57–65. doi:10.1016/j.cytogfr.2017.03.00328363692
   PubMed Web of Science ®Google Scholar
• Su H, Lei C-T, Zhang C. Interleukin-6 signaling pathway and its role in kidney disease: an update. Front Immunol. 2017;8(April):1–10. doi:10.3389/fimmu.2017.0000128149297
   PubMedGoogle Scholar
• Mack M. Inflammation and fibrosis. Hepatol Int Soc Matrix Biol. 2013;58(S1):281A– 284A.
   Google Scholar
• Zhang W, Wang W, Yu H, et al. Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension. 2012;59(1):136–144. doi:10.1161/HYPERTENSIONAHA.111.17332822068875
   PubMed Web of Science ®Google Scholar
• Garley M, Jabłońska E, Sawicka-Powierza J, et al. Expression of IL-1 and IL-6 and their natural regulators in leukocytes of B-cell chronic lymphocytic leukaemia patients. Adv Med Sci. 2016;61(2):187–192. doi:10.1016/j.advms.2015.12.00626876087
   PubMed Web of Science ®Google Scholar
• Wolf G. Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant. 2013;13(5):1131–1142. doi:10.1093/ndt/13.5.1131
   Google Scholar
• Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y. Chronic kidney disease, inflammation, and cardiovascular disease risk in rheumatoid arthritis. J Cardiol. 2017. doi:10.1016/j.jjcc.2017.08.008
   PubMedGoogle Scholar
• Cacho J, Sevillano J, de-Castro J, Herrera E, Ramos M. Validation of simple indexes to assess insulin sensitivity during pregnancy in wistar and Sprague-Dawley rats. Am J Physiol Endocrinol Metab. 2008;295:1269–1276. doi:10.1152/ajpendo.90207.2008
   PubMed Web of Science ®Google Scholar
• Ozbilgin S, Ozkardesler S, Akan M, et al. Renal ischemia/reperfusion injury in diabetic rats : the role of local ischemic preconditioning. Biomed Res Int. 2016;2016:8580475. doi:10.1155/2016/858047526925416
   PubMed Web of Science ®Google Scholar
• Leblond A, Lesage S, Cartee GD, Pichette V. Mechanism of insulin resistance in a rat model of kidney disease and the risk of developing type 2 diabetes. PLoS One. 2017;12:1–17.
   Web of Science ®Google Scholar
• Hussein M, Mahmoud G, Ibrahim G, Aly D, Mohammad A. Possible association of interleukin-1beta (−511C/T) and interleukin-6 (−174G/C) gene polymorphisms with atherosclerosis in end stage renal disease Egyptian patients on maintenance haemodialysis. Egypt J Med Hum Genet. 2013;14(3):267–275. doi:10.1016/j.ejmhg.2013.04.001
   Google Scholar
• Wihastuti TA, Sargowo D, Heriansyah T, Aziza YE, Iwana AN, Evitasari LA. The reduction of aorta histopathological images through inhibition of reactive oxygen species formation in hypercholesterolemia rattus norvegicus treated with polysaccharide peptide of Ganoderma lucidum. Iran J Basic Med Sci. 2014;18(9):514–519.
   Google Scholar
• Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651. doi:10.1101/cshperspect.a00165120457564
   PubMed Web of Science ®Google Scholar
• Heriansyah T, Hanifa H, Andarini S, Wihastuti TA. Darapladib inhibit adhesion molecule expression in aorta at early stages of atherosclerosis using Sprague-Dawley type 2 diabetes mellitus model. Asian J Pharma Clin Res. 2017;10(6):4–7.
   Google Scholar
• Heriansyah T, Adam AA, Wihastuti TA, Rohman MS. Elaborate evaluation of serum and tissue oxidized LDL level with darapladib therapy: a feasible diagnostic marker for early atherogenesis. Asian Pac J Trop Biomed. 2017;7(2):134–138. doi:10.1016/j.apjtb.2016.11.014
   Web of Science ®Google Scholar
• Heriansyah T, Wihastuti TA, Anita K, et al. Atherogenesis inhibition by darapladib administration in dyslipidemia model Sprague-Dawley rats. Natl J Physiol Pharm Pharmacol. 2015;6(1):1–7.
   Google Scholar
• Wang WY, Zhang J, Wu WY, et al. Inhibition of lipoprotein-associated phospholipase a2 ameliorates inflammation and decreases atherosclerotic plaque formation in apoE-deficient mice. PLoS One. 2011;6:8.
   Web of Science ®Google Scholar
• Pashkow FJ. Oxidative stress and inflammation in heart disease:do antioxidants have a role in treatment and/or prevention? Int J Inflam. 2011;2011(Figure 4):514623.21860805
   PubMedGoogle Scholar
• Wihastuti TA. Vasa vasorum anti-angiogenesis through H2O2, HIF-1 α, NF- κB, and iNOS inhibition by mangosteen pericarp ethanolic extract (Garcinia mangostana Linn) in hypercholesterol- diet-given Rattus norvegicus Wistar strain. Vasc Health Risk Manag. 2014;10:523–531.25187725
   PubMedGoogle Scholar
• Ridker PM. Targeting inflammatory pathways for the treatment of cardiovascular disease. Eur Heart J. 2014;35:540–543.24204011
   PubMed Web of Science ®Google Scholar
• Hassan M. STABILITY and SOLID-TIMI 52: lipoprotein associated phospholipase A 2 (Lp-PLA 2) as a biomarker or risk factor for cardiovascular diseases. Global Cardiol Sci Pract. 2015;6. doi:10.5339/gcsp.2015.6
   Google Scholar
• Mohler ER, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent. the results of a multicenter, randomized, double-Bl. J Am Coll Cardiol. 2008;51(17):1632–1641. doi:10.1016/j.jacc.2007.11.079.18436114
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312(10):1006–1015. doi:10.1001/jama.2014.1106125173516
   PubMed Web of Science ®Google Scholar
• White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. NEngl J Med. 2014;370(18):page 1702–1711.
   Web of Science ®Google Scholar